PATENT CLAIM ANALYSIS

Application Number: 16101882
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "375000"]

Abstract:
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

Claim (Index 21):
The method of  claim 19 , wherein the benzoxazole derivative is tafamidis.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14353459', '15448054', '15736826', '13830731', '15480139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8063575766720031
- 35 USC 102 Novelty (BERT): 0.6153090411547062
- Combined Prediction Score: 0.7872527231202734
- Mean Citation Score: 485.68719
- Max Citation Score: 735.84143
- Similarity Product: 455.0560782549464

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test